N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants Who Developed Psoriatic Arthritis (PsA) — 47.4; 35.7; 17.3; 10.3 Percentage of participants
N/A N=171 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic Arthritis
Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score
Phase 4 N=1,013 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 4 N=752 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis — 176; 119 participants
Phase 2 N=100 Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores — -12.46; -13.35; -18.02; -4.18 scores on a scale
Phase 2 N=165 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Arthritis, Psoriatic
Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 4 N=308 Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008
N/A N=18 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Psoriasis
Primary: Percentage Change in Endothelial Function Compared to Baseline. — -1.414 percent change — p=<0.05
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
N/A N=96 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months — -1.4 units on a scale
Phase 3 N=504 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Phase 3 N=442 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001
N/A N=734 Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)
Psoriasis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Serious Adverse Drug Reactions (SADRs), Deaths, and…
N/A N=145 The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change in Heart Rate Variability (HRV) Measure — 13.38; -13.48 ms
Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 2 N=331 The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6 — 28.0; 22.8; 8.3 percentage of participants…
Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Psoriasis
Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…
Phase 4 N=63 Subclinical Cardiovascular Disease in Psoriatic Disease
Cardiovascular Diseases · Myocardial Infarction · Atherosclerotic Cardiovascular Disease
Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 3 N=480 A Study of Golimumab in Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 — 21.8; 75.1 Percentage of Participants — p=<0.001
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
Phase 3 N=528 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062
Phase 3 N=432 Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Scalp Psoriasis
Primary: Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 — 66.4; 27.8 percentage of participants — p=<0.0001